{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:11:51Z","timestamp":1779912711400,"version":"3.53.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Services Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40273-022-01189-9","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T01:02:47Z","timestamp":1664499767000},"page":"1159-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"40","author":[{"given":"Rumjhum","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"1189_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/DDDT.S191303","volume":"13","author":"S Flis","year":"2019","unstructured":"Flis S, Chojnacki T. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Des Devel Ther. 2019;13:825\u201343.","journal-title":"Drug Des Devel Ther."},{"issue":"5","key":"1189_CR2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","volume":"36","author":"A Granatowicz","year":"2015","unstructured":"Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M. An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med. 2015;36(5):197\u2013202.","journal-title":"Korean J Fam Med."},{"key":"1189_CR3","unstructured":"Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order). Orphanet report series, Number 1, January 2022. https:\/\/www.orpha.net\/orphacom\/cahiers\/docs\/GB\/Prevalence_of_rare_diseases_by_alphabetical_list.pdf."},{"key":"1189_CR4","unstructured":"Cancer Stat Facts: Leukemia-Chronic Myeloid Leukemia (CML) [Internet]. National Cancer Institute Surveillance Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html"},{"issue":"10","key":"1189_CR5","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385\u2013415.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"1189_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE, Talpaz M, O\u2019Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306\u201315.","journal-title":"Cancer"},{"issue":"Suppl_4","key":"1189_CR7","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen J, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv41-51.","journal-title":"Ann Oncol"},{"issue":"4","key":"1189_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"1","key":"1189_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1189_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1185\/03007995.2015.1120189","volume":"32","author":"LJ McGarry","year":"2016","unstructured":"McGarry LJ, Chen YJ, Divino V, Pokras S, Taylor CR, Munakata J, et al. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin. 2016;32(2):289\u201399.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1189_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40261-018-0706-5","volume":"38","author":"J Fu","year":"2018","unstructured":"Fu J, Liu Y, Lin H, Wu B. Economic evaluations of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in middle- and high-income countries: a systematic review. Clin Drug Investig. 2018;38(12):1167\u201378.","journal-title":"Clin Drug Investig"},{"key":"1189_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1189_CR13","unstructured":"National Institute for Health and Care Excellence (NICE). Single technology appraisal: user guide for company evidence submission template. 2017. https:\/\/www.nice.org.uk\/process\/pmg24\/chapter\/instructions-for-companies."},{"issue":"7052","key":"1189_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275\u201383.","journal-title":"BMJ"},{"issue":"Suppl_1","key":"1189_CR15","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1182\/blood-2019-121833","volume":"134","author":"AM Adel","year":"2019","unstructured":"Adel AM, Abushanab D, Hamad A, Abdulla MA-J, Yassin MA. Dasatinib and nilotinib as upfront therapy for chronic-phase chronic myeloid leukemia (CML-CP) in Qatar: a cost effectiveness analysis (CEA). Blood. 2019;134(Suppl_1):5850.","journal-title":"Blood"},{"key":"1189_CR16","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.jval.2018.07.830","volume":"21","author":"BN Borissov","year":"2018","unstructured":"Borissov BN. Cost- effectiveness of deep molecular response with first- line nilotinib vs. imatinib in ph+ chronic myeloid leukaemia measured by effectively treated patient- years in Bulgaria. Value Health. 2018;21:S108.","journal-title":"Value Health."},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1182\/blood-2019-127530","volume":"134","author":"RT Centrone","year":"2019","unstructured":"Centrone RT, Bonafe I, Miranda EC, Seguro FS, Magalhaes GHR, Clementino ND, et al. Financial impact of imatinib discontinuation in Brazil: a pharmoeconomic study. Blood. 2019;134:5844.","journal-title":"Blood"},{"key":"1189_CR18","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jval.2020.04.1616","volume":"23","author":"M Da Costa","year":"2020","unstructured":"Da Costa M, Schaffel R, Lira R. PCN126 Cost-effectiveness of second generation TKIs compared with imatinib for chronic myeloid leukaemia: implications of treatment-free remission. Value Health. 2020;23:S45.","journal-title":"Value Health."},{"key":"1189_CR19","first-page":"63","volume":"9","author":"JKL Darba","year":"2012","unstructured":"Darba JKL. Cost-effectiveness analysis of dasatinib versus high-dose imatinib in the treatment of chronic myeloid leukemia in patients resistant to standard doses of imatinib. Pharmacoeconomics. 2012;9:63\u201371.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1189_CR20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/0284186X.2010.495132","volume":"49","author":"O Ghatnekar","year":"2010","unstructured":"Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib: a Swedish model application. Acta Oncol. 2010;49(6):851\u20138.","journal-title":"Acta Oncol"},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1016\/j.jval.2018.04.1712","volume":"21","author":"L Guan","year":"2018","unstructured":"Guan L, Huang C, Liu Y. Cost-effectiveness analysis of nilotinib versus high-dose imatinib for the second-line treatment of chronic myeloid leukemia in China: based on nation-wide data. Value Health. 2018;21:S254.","journal-title":"Value Health."},{"issue":"4","key":"1189_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40258-019-00489-0","volume":"17","author":"C Hirt","year":"2019","unstructured":"Hirt C, Iannazzo S, Chiroli S, McGarry LJ, le Coutre P, Stenke L, et al. Cost effectiveness of the third-generation tyrosine kinase inhibitor (TKI) ponatinib, vs. second-generation TKIs or stem cell transplant, as third-line treatment for chronic-phase chronic myeloid leukemia. Appl Health Econ Health Policy. 2019;17(4):555\u201367.","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"1189_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/13696998.2019.1618316","volume":"22","author":"EJ Jabbour","year":"2019","unstructured":"Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. J Med Econ. 2019;22(11):1113\u20138.","journal-title":"J Med Econ"},{"issue":"4","key":"1189_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.clinthera.2014.02.008","volume":"36","author":"W Kulpeng","year":"2014","unstructured":"Kulpeng W, Sompitak S, Jootar S, Chansung K, Teerawattananon Y. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Ther. 2014;36(4):534\u201343.","journal-title":"Clin Ther"},{"issue":"4","key":"1189_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/13696998.2016.1261032","volume":"20","author":"N Li","year":"2017","unstructured":"Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, et al. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. J Med Econ. 2017;20(4):328\u201336.","journal-title":"J Med Econ"},{"issue":"1","key":"1189_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","volume":"38","author":"N Li","year":"2018","unstructured":"Li N, Zheng B, Cai HF, Yang J, Luo XF, Weng LZ, et al. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China. Clin Drug Investig. 2018;38(1):79\u201386.","journal-title":"Clin Drug Investig"},{"key":"1189_CR27","doi-asserted-by":"publisher","first-page":"S470","DOI":"10.1016\/j.jval.2019.09.372","volume":"22","author":"V Maheshwari","year":"2019","unstructured":"Maheshwari V, Tran D, Agostoni G, Filioussi K, Viana R. PCN176 Cost-effectiveness of second-line nilotinib versus dasatinib for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia-chronic phase (PH+ CML-CP) in Italy. Value Health. 2019;22:S470.","journal-title":"Value Health."},{"issue":"Suppl 1","key":"1189_CR28","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2018-99-116422","volume":"132","author":"B Nam","year":"2018","unstructured":"Nam B, Kim S, Lee JH, Yoo KH, Ahn J-Y, Kim H. Study of treatment-free remission evaluation in real-world chronic myeloid leukemia; cost-effectiveness analysis. Blood. 2018;132(Suppl 1):4261.","journal-title":"Blood"},{"issue":"10","key":"1189_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jval.2020.05.019","volume":"23","author":"JT Nguyen","year":"2020","unstructured":"Nguyen JT, Cole AL, Leech AA, Wood WA, Dusetzina SB. Cost-effectiveness of first-line tyrosine kinase inhibitor therapy initiation strategies for chronic myeloid leukemia. Value Health. 2020;23(10):1292\u20139.","journal-title":"Value Health."},{"issue":"7","key":"1189_CR30","doi-asserted-by":"publisher","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","volume":"108","author":"WV Padula","year":"2016","unstructured":"Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J Natl Cancer Inst. 2016;108(7):djw003.","journal-title":"J Natl Cancer Inst"},{"key":"1189_CR31","doi-asserted-by":"crossref","unstructured":"Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treat. 2015;2015:982395.","DOI":"10.1155\/2015\/982395"},{"issue":"8","key":"1189_CR32","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3109\/10428194.2014.982635","volume":"56","author":"U Rochau","year":"2015","unstructured":"Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, et al. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2015;56(8):2315\u201325.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1189_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7705\/biomedica.v34i1.1446","volume":"34","author":"M Romero","year":"2014","unstructured":"Romero M, Ch\u00e1vez D, De Los RM, Alvis-Guzm\u00e1n N. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica. 2014;34(1):48\u201359.","journal-title":"Biomedica"},{"issue":"11 Suppl","key":"1189_CR34","first-page":"S265","volume":"18","author":"Y Sanchez","year":"2012","unstructured":"Sanchez Y, Penrod JR, Qiu XL, Romley J, Thornton Snider J, Philipson T. The option value of innovative treatments in the context of chronic myeloid leukemia. Am J Manag Care. 2012;18(11 Suppl):S265\u201371.","journal-title":"Am J Manag Care"},{"issue":"4","key":"1189_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/13696998.2016.1271336","volume":"20","author":"G Sheng","year":"2017","unstructured":"Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, et al. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. J Med Econ. 2017;20(4):371\u201381.","journal-title":"J Med Econ"},{"issue":"8","key":"1189_CR36","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","volume":"6","author":"YT Shih","year":"2019","unstructured":"Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019;6(8):e398-408.","journal-title":"Lancet Haematol."},{"issue":"5","key":"1189_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3111\/13696998.2015.1126285","volume":"19","author":"J Whalen","year":"2016","unstructured":"Whalen J, Stillman I, Ambavane A, Felber E, Makenbaeva D, Bolinder B. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. J Med Econ. 2016;19(5):445\u201361.","journal-title":"J Med Econ"},{"key":"1189_CR38","doi-asserted-by":"publisher","first-page":"S447","DOI":"10.1016\/j.jval.2019.09.261","volume":"22","author":"S Wolters","year":"2019","unstructured":"Wolters S, Dijkstra J, Arons A, Ijzermans A, Postma M. PCN64 Cost-effectiveness of imatinib since its introduction as first-line treatment in the Netherlands. Value Health. 2019;22:S447\u20138.","journal-title":"Value Health."},{"issue":"29","key":"1189_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007445","volume":"96","author":"B Wu","year":"2017","unstructured":"Wu B, Liu M, Li T, Lin H, Zhong H. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: a CHEERS-compliant article. Medicine (Baltimore). 2017;96(29): e7445.","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"1189_CR40","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","volume":"3","author":"C Yamamoto","year":"2019","unstructured":"Yamamoto C, Nakashima H, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019;3(21):3266\u201377.","journal-title":"Blood Adv"},{"issue":"11 Suppl","key":"1189_CR41","first-page":"S257","volume":"18","author":"W Yin","year":"2012","unstructured":"Yin W, Penrod JR, Maclean R, Lakdawalla DN, Philipson T. Value of survival gains in chronic myeloid leukemia. Am J Manag Care. 2012;18(11 Suppl):S257\u201364.","journal-title":"Am J Manag Care"},{"key":"1189_CR42","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jval.2019.04.208","volume":"22","author":"X Yue","year":"2019","unstructured":"Yue X, Hincapie A, Huang B, Guo JJ. PCN84 Effectiveness and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the United States. Value Health. 2019;22:S71.","journal-title":"Value Health."},{"issue":"S1","key":"1189_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000060","volume":"2","author":"H Zhu","year":"2018","unstructured":"Zhu H, Cs XJ, Wu J, Zhang Y, Song Y, Luo J, et al. Real world evidence based cost-effectiveness analyses (CEA) of nilotinib versus imatinib as first-line treatment in the management of chronic myeloid leukemia (CML) in China. HemaSphere. 2018;2(S1):1\u20131113.","journal-title":"HemaSphere."},{"issue":"1","key":"1189_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s41669-021-00286-3","volume":"6","author":"M Bonifacio","year":"2022","unstructured":"Bonifacio M, Maheshwari V, Tran D, Agostoni G, Filioussi K, Viana R. Economic model to evaluate the cost-effectiveness of second-line nilotinib versus dasatinib for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP) in Italy. Pharmacoecon Open. 2022;6(1):95\u2013104.","journal-title":"Pharmacoecon Open."},{"issue":"8","key":"1189_CR45","first-page":"1077","volume":"27","author":"RM Conti","year":"2021","unstructured":"Conti RM, Padula WV, Becker RV, Salamone S. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. J Manag Care Spec Pharm. 2021;27(8):1077\u201385.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1189_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40258-021-00666-0","volume":"19","author":"B Muresan","year":"2021","unstructured":"Muresan B, Mamolo C, Cappelleri JC, Postma MJ, Heeg B. Cost-effectiveness of bosutinib for the treatment of adult patients with chronic phase chronic myeloid leukemia in the second-line setting. Appl Health Econ Health Policy. 2021;19(6):929\u201340.","journal-title":"Appl Health Econ Health Policy"},{"key":"1189_CR47","first-page":"1","volume":"15","author":"X Yue","year":"2021","unstructured":"Yue X, Hincapie AL, Li Y, Guo JJ. Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States. Leuk Lymphoma. 2021;15:1\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"1189_CR48","doi-asserted-by":"publisher","first-page":"A280","DOI":"10.1016\/S1098-3015(10)74375-8","volume":"12","author":"E Asano","year":"2009","unstructured":"Asano E, Nita M, Moellmann-Coelho A, Rached R, Donato B, Rahal E. PCN124 Cost-utility analysis of dasatinib in patients with imatinib-resistant chronic myeloid leukemia (CML) on chronic (CP), accelerated (AP) and blast (BP) phases in Brazil. Value Health. 2009;12(7):A280\u20131.","journal-title":"Value Health."},{"issue":"1\u20132","key":"1189_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/10428190109057960","volume":"41","author":"JR Beck","year":"2001","unstructured":"Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk Lymphoma. 2001;41(1\u20132):117\u201324.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1189_CR50","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3111\/13696990802354683","volume":"11","author":"L Breitscheidel","year":"2008","unstructured":"Breitscheidel L. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. J Med Econ. 2008;11(4):571\u201384.","journal-title":"J Med Econ"},{"issue":"Suppl 3","key":"1189_CR51","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1111\/j.1524-4733.2009.00635.x","volume":"12","author":"Z Chen","year":"2009","unstructured":"Chen Z, Wang C, Xu X, Feng W. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health. 2009;12(Suppl 3):S85\u20138.","journal-title":"Value Health"},{"issue":"5","key":"1189_CR52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","volume":"23","author":"K Dalziel","year":"2005","unstructured":"Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. 2005;23(5):515\u201326.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"1189_CR53","doi-asserted-by":"publisher","first-page":"A495","DOI":"10.1016\/S1098-3015(10)75341-9","volume":"12","author":"A Juarez-Garcia","year":"2009","unstructured":"Juarez-Garcia A, Uc-Coyoc R, Hernandez-Rivera G, Rangel S, Taylor MJ, Litalien G, et al. The cost and cost effectiveness of dasatinib (SPRYCEL) 100 MG therapy for the management of imatinib resistant and intolerant patients in chronic phase with chronic myeloid leukemia (CML) in M\u00e9xico. Value Health. 2009;12(7):A495.","journal-title":"Value Health."},{"issue":"7","key":"1189_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-125-7-199610010-00002","volume":"125","author":"MW Kattan","year":"1996","unstructured":"Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996;125(7):541\u20138.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1189_CR55","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood.V92.11.4047","volume":"92","author":"SJ Lee","year":"1998","unstructured":"Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998;92(11):4047\u201352.","journal-title":"Blood"},{"issue":"7","key":"1189_CR56","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1200\/JCO.1997.15.7.2673","volume":"15","author":"NL Liberato","year":"1997","unstructured":"Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol. 1997;15(7):2673\u201382.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1189_CR57","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/A:1008212411489","volume":"9","author":"A Messori","year":"1998","unstructured":"Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol. 1998;9(4):389\u201396.","journal-title":"Ann Oncol"},{"issue":"5","key":"1189_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00019053-200826050-00007","volume":"26","author":"SD Reed","year":"2008","unstructured":"Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics. 2008;26(5):435\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"22","key":"1189_CR59","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood.V114.22.2474.2474","volume":"114","author":"Z Shen","year":"2009","unstructured":"Shen Z, Huang X, de Costa SM, Chen Z, Xu X, Wang Q, et al. Cost-effectiveness of imatinib in comparison with bone marrow transplant in chronic phase (CP) chronic myeloid leukaemia (CML) in China. Blood. 2009;114(22):2474.","journal-title":"Blood"},{"issue":"3","key":"1189_CR60","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1592\/phco.25.3.325.61593","volume":"25","author":"GH Skrepnek","year":"2005","unstructured":"Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005;25(3):325\u201334.","journal-title":"Pharmacotherapy"},{"issue":"22","key":"1189_CR61","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1182\/blood.V114.22.4535.4535","volume":"114","author":"MJ Taylor","year":"2009","unstructured":"Taylor MJ, Saxby RC, Davis C. An economic evaluation of dasatinib for the treatment of imatinib-resistant patients with chronic myelogenous leukaemia. Blood. 2009;114(22):4535.","journal-title":"Blood"},{"issue":"11","key":"1189_CR62","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.clinthera.2004.11.007","volume":"26","author":"E Warren","year":"2004","unstructured":"Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther. 2004;26(11):1924\u201333.","journal-title":"Clin Ther"},{"key":"1189_CR63","volume-title":"Re-submission: bosutinib 100mg, 500mg film-coated tablets (Bosulif\u00ae). SMC No. (910\/13)","author":"SMC","year":"2015","unstructured":"SMC. Re-submission: bosutinib 100mg, 500mg film-coated tablets (Bosulif\u00ae). SMC No. (910\/13). SMC; 2015."},{"key":"1189_CR64","volume-title":"Dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel\u00ae). SMC No (1170\/16)","author":"SMC","year":"2016","unstructured":"SMC. Dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel\u00ae). SMC No (1170\/16). SMC; 2016."},{"key":"1189_CR65","volume-title":"Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)","author":"NICE","year":"2016","unstructured":"NICE. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425). NICE; 2016."},{"key":"1189_CR66","volume-title":"PCODR Expert Review Committee (PERC) final recommendation: Bosulif for chronic myeloid leukemia (pCODR 10039)","author":"CADTH","year":"2015","unstructured":"CADTH. PCODR Expert Review Committee (PERC) final recommendation: Bosulif for chronic myeloid leukemia (pCODR 10039). CADTH; 2015."},{"key":"1189_CR67","unstructured":"All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat assessment report. Ponatinib (Iclusig\u00ae) 15 mg and 45 mg film-coated tablets. Reference number: 1163. October 2014. AWMSG; 2014."},{"key":"1189_CR68","volume-title":"Resubmission: PONATINIB tablet, 15 mg and 45 mg, Iclusig\u00ae, Specialized Therapeutics","author":"PBAC","year":"2015","unstructured":"PBAC. Resubmission: PONATINIB tablet, 15 mg and 45 mg, Iclusig\u00ae, Specialized Therapeutics. PBAC; 2015."},{"key":"1189_CR69","volume-title":"Bosutinib for previously treated chronic myeloid leukemia","author":"NICE","year":"2016","unstructured":"NICE. Bosutinib for previously treated chronic myeloid leukemia. NICE; 2016."},{"key":"1189_CR70","volume-title":"Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia Committee Papers","author":"NICE","year":"2017","unstructured":"NICE. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia Committee Papers. NICE; 2017."},{"key":"1189_CR71","volume-title":"Ponatinib 15mg, 45mg film-coated tablets (Iclusig\u00ae) SMC No. (1032\/15)","author":"SMC","year":"2015","unstructured":"SMC. Ponatinib 15mg, 45mg film-coated tablets (Iclusig\u00ae) SMC No. (1032\/15). Berlin: SMC; 2015."},{"key":"1189_CR72","volume-title":"PCODR Expert Review Committee (PERC) final recommendation (pCODR 10056): Iclusig\u00ae for chronic myeloid leukemia\/acute lymphoblastic leukemia","author":"CADTH","year":"2015","unstructured":"CADTH. PCODR Expert Review Committee (PERC) final recommendation (pCODR 10056): Iclusig\u00ae for chronic myeloid leukemia\/acute lymphoblastic leukemia. CADTH; 2015."},{"key":"1189_CR73","volume-title":"The effectiveness and cost effectiveness of imatinib for first line treatment of chronic myeloid leukemia in chronic phase","author":"NICE","year":"2003","unstructured":"NICE. The effectiveness and cost effectiveness of imatinib for first line treatment of chronic myeloid leukemia in chronic phase. NICE; 2003."},{"key":"1189_CR74","volume-title":"Nilotinib 150mg hard capsules (Tasigna\u00ae) SMC No. (709\/11)","author":"SMC","year":"2011","unstructured":"SMC. Nilotinib 150mg hard capsules (Tasigna\u00ae) SMC No. (709\/11). SMC; 2011."},{"key":"1189_CR75","volume-title":"Dasatinib, tablets, 20 mg, 50 mg, 70 mg and 100 mg, Sprycel\u00ae","author":"PBAC","year":"2011","unstructured":"PBAC. Dasatinib, tablets, 20 mg, 50 mg, 70 mg and 100 mg, Sprycel\u00ae. PBAC; 2011."},{"key":"1189_CR76","volume-title":"Nilotinib, capsule, 150 mg, Tasigna\u00ae","author":"PBAC","year":"2011","unstructured":"PBAC. Nilotinib, capsule, 150 mg, Tasigna\u00ae. PBAC; 2011."},{"key":"1189_CR77","volume-title":"Multiple technology appraisal (MTA) Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia (incl part-review of TA 70)","author":"NICE","year":"2016","unstructured":"NICE. Multiple technology appraisal (MTA) Dasatinib, nilotinib and standard-dose imatinib for the first line treatment of chronic myeloid leukaemia (incl part-review of TA 70). NICE; 2016."},{"key":"1189_CR78","volume-title":"Re-submission: dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel\u00ae) SMC N.o (370\/07)","author":"SMC","year":"2016","unstructured":"SMC. Re-submission: dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel\u00ae) SMC N.o (370\/07). SMC; 2016."},{"issue":"1","key":"1189_CR79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-4733.2009.00573.x","volume":"13","author":"SM Szabo","year":"2010","unstructured":"Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health. 2010;13(1):103\u201311.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01189-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T04:37:55Z","timestamp":1701146275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01189-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01189-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"4 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rumjhum Agrawal, Harish Negi, and Tanvi Rajput are employees of Novartis Healthcare Pvt Ltd. Joao Vieira and Jacqueline Ryan are employees of Novartis Pharmaceuticals UK Ltd. Regina Corbin is an employee and stockholder of Novartis Services Inc. Ricardo Viana is an employee and stockholder of Novartis Pharma AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data generated during and\/or analyzed in the current study can be obtained from the first author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"RA, RC, and RV conceptualized the study and all authors contributed to the study design. HN, RA, and TR conducted the literature search, data extraction, initial summary of results, and quality assessment. All authors contributed to data interpretation and development of the manuscript, including the figures, tables, and online resource materials. All authors approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}